CFDE Data Portal | Search REXO5

	Label	Description
	REXO5 Gene (Entity type)	ENSG00000005189 - RNA exonuclease 5
	KFGENEBIN:REXO5-variant-count CUI gene has variants REXO5 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from Kids First
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 5 PACLITAXEL HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE131887 5 V 2 DOXYCYCLINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 1 V 3 PROGESTERONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 3 V 5 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE95077 1 V 2 AMILORIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

REXO5

ENSG00000005189 - RNA exonuclease 5

KFGENEBIN:REXO5-variant-count CUI gene has variants REXO5

A Knowledge Graph Assertion from Kids First

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

A Gene Set from LINCS

GSE172016 2 V 5 PACLITAXEL HUMAN UP

A Gene Set from LINCS

GSE131887 5 V 2 DOXYCYCLINE MOUSE UP

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE220806 1 V 3 PROGESTERONE HUMAN UP

A Gene Set from LINCS

GSE135350 3 V 5 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

A Gene Set from LINCS

GSE95077 1 V 2 AMILORIDE HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.